Protein kinases C: A new cytoplasmic target;Protéines kinases C: Une nouvelle cible cytoplasmique

Bulletin du Cancer

Volumn 95, Issue 7-8, 2008, Pages 683-689

  Vignot, Stéphane ^a   Soria, Jean Charles ^b   Spano, Jean Philippe ^a   Mounier, Nicolas ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Molecular targetted therapy; Protein kinase C

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; APRINOCARSEN; BRYOSTATIN 1; CAPECITABINE; CARBOPLATIN; CISPLATIN; CPG 41251; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ENZASTAURIN; ENZASTAURINE; FLAVOPIRIDOL; FLUOROURACIL; GEMCITABINE; IMATINIB; ISIS 3521; ISOENZYME; LOMUSTINE; MIDOSTAURIN; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; PROTEIN SERINE THREONINE KINASE; RITUXIMAB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; DRUG DERIVATIVE; INDOLE DERIVATIVE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN KINASE INHIBITOR; STAUROSPORINE; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BRAIN TUMOR; BRONCHUS CANCER; CARCINOGENESIS; CELL TYPE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOPENIA; CYTOPLASM; DEREGULATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME REGULATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; HUMAN; HYPERGLYCEMIA; LYMPHOMA; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; PROTEIN EXPRESSION; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; URINE COLOR; VOMITING; DRUG ANTAGONISM; ENZYMOLOGY; NEOPLASM; PHYSIOLOGY;

CYTOPLASM; INDOLES; ISOENZYMES; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; STAUROSPORINE;

EID: 51349137903     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0665     Document Type: Review

References (91)

1. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 1982; 257: 7847-51.
2. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-5.
3. Parker PJ, Murray-Rust J. PKC at a glance. J Cell Sci 2004; 117: 131-2.
4. Nishizuka Y, Nakamura S. Lipid mediators and protein kinase C for intra-cellular signalling. Clin Exp Pharmacol Physiol Suppl 1995; 22: S202-S203.
5. Griner EM, Kazanietz MG. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-94.
6. Wang QJ, Bhattacharyya D, Garfield S, Nacro K, Marquez VE, Blumberg PM. Differential localization of protein kinase C delta by phorbol esters and related compounds using a fusion protein with green fluorescent protein. J Biol Chem 1999; 274: 37233-9.
7. Lee HW, Smith L, Pettit GR, Vinitsky A, Smith JB. Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem 1996; 271: 20973-6.
8. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol 1998; 18: 839-45.
9. Leontieva OV, Black JD. Identification of two distinct pathways of protein kinase C-alpha down-regulation in intestinal epithelial cells. J Biol Chem 2004; 279: 5788-801.
10. Basu A. The potential of protein kinase C as a target for anticancer treatment. Pharmacol Ther 1993; 59: 257-80.
11. Baron-Delage S, Cherqui G. [Protein kinase C and tumorigenic potential]. Bull Cancer 1997; 84: 829-32.
12. Alvaro V, Levy L, Dubray C, et al. Invasive human pituitary tumors express a point-mutated protein kinase C-alpha. J Clin Endocrinol Metab 1993; 77: 1125-9.
13. Knauf JA, Elisei R, Mochly-Rosen D, et al. Involvement of protein kinase C-epsilon (PKC-epsilon) in thyroid cell death. A truncated chimeric PKC-epsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. J Biol Chem 1999; 274: 23414-25.
14. Zhu Y, Dong Q, Tan BJ, Lim WG, Zhou S, Duan W. The PKC-alpha-D294G mutant found in pituitary and thyroid tumors fails to transduce extracellular signals. Cancer Res 2005; 65: 4520-4.
15. Varga A, Czifra G, Tallai B, et al. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol 2004; 46: 462-5.
16. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005; 18: 1377-84.
17. Pan Q, Ban LW, Kleer CG, et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005; 65: 8366-71.
18. Borner C, Ueffing M, Jaken S, Parker PJ, Weinstein IB. Two closely related isoforms of protein kinase C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms. J Biol Chem 1995; 270: 78-86.
19. Mischak H, Goodnight JA, Kolch W, et al. Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 1993; 268: 6090-6.
20. Ainsworth PD, Winstanley JH, Pearson JM, Bishop HM, Garrod DR. Protein kinase C-alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma. Eur J Cancer 2004; 40: 2269-73.
21. Kerfoot C, Huang W, Rotenberg SA. Immunohistochemical analysis of advanced human breast carcinomas reveals down regulation of protein kinase C-alpha. J Histochem Cytochem 2004; 52: 419-22.
22. Han EK, Cacace AM, Sgambato A, Weinstein IB. Altered expression of cyclins and c-fos in R6 cells that overproduce PKC-epsilon. Carcinogenesis 1995; 16: 2423-8.
23. Basu A, Weixel KM. Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int J Cancer 1995; 62: 457-60.
24. Ding L, Wang H, Lang W, Xiao L. Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. J Biol Chem 2002; 277: 35305-13.
25. Jackson DN, Foster DA. The enigmatic protein kinase C-delta: complex roles in cell proliferation and survival. FASEB J 2004; 18: 627-36
26. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C-beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-9.
27. Oberschmidt O, Eismann U, Schulz L, et al. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro. Int J Clin Pharmacol Ther 2005; 43: 603-4.
28. Hanauske AR, Oberschmidt O, Hanauske-Abel H, Lahn MM, Eismann U. Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in vitro [corrected] soft-agar cloning experiments. Invest New Drugs 2007; 25: 205-10.
29. Carducci MA, Musib L, Kies MS, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C-beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24: 4092-9.
30. Hanauske A, Musib L, Weigang-Kohler K, et al. Comparison of enzastaurin pharmacokinetics and safety in the once daily (QD) and twice daily (BID) dose regimens: A phase I study. ASCO Meeting Abstracts 2007; 25: 14021.
31. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-6.
32. Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 19: 247-53.
33. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high-grade gliomas. J Clin Oncol 2005; 23: 1504; (Meeting Abstracts).
34. Bepler G, Oh Y, Burris H, Cleverly A, Lahn M, Herbst RS. A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2007; 25: 7543.
35. Podar K, Raab MS, Zhang J, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-77.
36. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109: 4964-72.
37. Beerepoot L, Rademaker-Lakhai J, Witteveen E, et al. Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer. ASCO Meeting Abstracts 2006; 24: 2046.
38. Butowski NA, Lamborn K, Chang S, et al. Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma. ASCO Meeting Abstracts 2007; 25: 12511.
39. Leong S, Camidge R, Eckhardt G, et al. A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. ASCO Meeting Abstracts 2006; 24: 2048.
40. Hanauske A, Weigang Koehler K, Yilmaz E, et al. Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. ASCO Meeting Abstracts 2006; 24: 2047.
41. Denham DW, Franz MG, Denham W, et al. Directed antisense therapy confirms the role of protein kinase C-alpha in the tumorigenicity of pancreatic cancer. Surgery 1998; 124: 218-23; (discussion 223-4).
42. Dennis JU, Dean NM, Bennett CF, Griffith JW, Lang CM, Welch DR. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha. Cancer Lett 1998; 128: 65-70.
43. Yazaki T, Ahmad S, Chahlavi A, et al. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. Mol Pharmacol 1996; 50: 236-42.
44. Shen L, Dean NM, Glazer RI. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multi-forme cells by a protein kinase C-alpha antisense oligonucleotide. Mol Pharmacol 1999; 55: 396-402.
45. Nemunaitis J, Holmlund JT, Kraynak M, et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 1999; 17: 3586-95.
46. Yuen AR, Halsey J, Fisher GA, et al. Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999; 5: 3357-63.
47. Advani R, Lum BL, Fisher GA, et al. A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs 2005; 23: 467-77.
48. Rao S, Watkins D, Cunningham D, et al. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann Oncol 2004; 15: 1413-8.
49. Cripps MC, Figueredo AT, Oza AM, et al. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Clin Cancer Res 2002; 8: 2188-92.
50. Marshall JL, Eisenberg SG, Johnson MD, et al. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2004; 4: 268-74.
51. Grossman SA, Alavi JB, Supko JG, et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro-oncol 2005; 7: 32-40.
52. Advani R, Peethambaram P, Lum BL, et al. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C-alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 2004; 100: 321-6.
53. Tolcher AW, Reyno L, Venner PM, et al. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2002; 8: 2530-5.
54. Mani S, Rudin CM, Kunkel K, et al. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002; 8: 1042-8.
55. Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 6086-93.
56. Vansteenkiste J, Canon JL, Riska H, et al. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer. Invest New Drugs 2005; 23: 263-9.
57. Ritch P, Rudin CM, Bitran JD, et al. Phase II study of PKC-alpha anti-sense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2006; 52: 173-80.
58. Lynch TJ, Raju R, Lind M, et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc Am Soc Clin Oncol 2003; 22; [(abstr 2504) 2003].
59. Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006; 24: 1428-34.
60. Lansiaux A, Fabbro D, Meyer T, Hamy F, Bailly C. [Pkt 412]. Bull Cancer 1999; 86: 614-7.
61. Fabbro D, Ruetz S, Bodis S, et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17-28.
62. Propper DJ, McDonald AC, Man A, et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001; 19: 1485-92.
63. Eder Jr. JP, Garcia-Carbonero R, Clark JW, et al. A phase I trial of daily oral 4′- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluoro-uracil in patients with advanced solid malignancies. Invest New Drugs 2004; 22: 139-50.
64. Monnerat C, Henriksson R, Le Chevalier T, et al. Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. Ann Oncol 2004; 15: 316-23.
65. Knapper S, Mills KI, Gilkes AF, Austin SJ, Walsh V, Burnett AK. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006; 108: 3494-503.
66. Heidel F, Solem FK, Breitenbuecher F, et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293-300.
67. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60.
68. Weisberg E, Wright RD, Jiang J, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006; 131: 1734-42.
69. Takahashi I, Saitoh Y, Yoshida M, et al. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot (Tokyo) 1989; 42: 571-6.
70. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996; 219: 778-83.
71. Akiyama T, Yoshida T, Tsujita T, et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997; 57: 1495-501.
72. Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 1998; 58: 3248-53.
73. Tamura T, Sasaki Y, Minami H, et al. Phase I Study of UCN-01 By 3-Hour Infusion. Proc Am Soc Clin Oncol 1999; 18 (abstr 611).
74. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19: 2319-33.
75. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxy-staurosporine in combination with fluorouracil in patients with advanced solid tumors. J Clin Oncol 2005; 23: 1875-84.
76. Mutter R, Wills M. Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 2000; 8: 1841-60.
77. Choi SH, Hyman T, Blumberg PM. Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase C-delta. Cancer Res 2006; 66: 7261-9.
78. Wender PA, Cribbs CM, Koehler KF, et al. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci USA 1988; 85: 7197-201.
79. Asiedu C, Biggs J, Lilly M, Kraft AS. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 1995; 55: 3716-20.
80. Prendiville J, Crowther D, Thatcher N, et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 1993; 68: 418-24.
81. Philip PA, Rea D, Thavasu P, et al. Phase I study of bryostatin 1: assessment of interleukin-6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst 1993; 85: 1812-8.
82. Jayson GC, Crowther D, Prendiville J, et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br J Cancer 1995; 72: 461-8.
83. Varterasian ML, Mohammad RM, Eilender DS, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol 1998; 16: 56-62.
84. Lansiaux A, Bailly C. [Perspectives on the oncologist pharmacopoeia]. Bull Cancer 2003; 90: 25-30.
85. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001; 7: 2168-81.
86. Ilson D, Shah M, O'Reilly E, et al. A Phase II Trial of Weekly One-Hour Paclitaxel Followed by Bryostatin-1 in Patients with Advanced Esophageal Cancer: an Active New Drug Combination. Proc Am Soc Clin Oncol 2001; 20: 159a (abstr 633).
87. Charoentum C, Maeur AM, Gajewsky TF, et al. Phase II Study of Bryostatin-1 in Combination with Paclitaxel for Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20:271b (abstr 2834).
88. Watkins V, Hong S, Lin B. Enzastaurin safety review: Data from phase I and phase II trials. ASCO Meeting Abstracts 2006; 24: 13077.
89. Green LJ, Marder P, Ray C, et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 2006; 12: 3408-15.
90. Oberschmidt O, Eismann U, Lahn MM, et al. In vitro chemosensitivity against enzastaurin correlates with gene expression of IL8 and GSK3-beta. ASCO Meeting Abstracts 2006; 24: 13046.
91. Meinhold-Heerlein I, Brautigam K, Bauerschlag D, et al. Effects of PKC beta inhibitor enzastaurin on chemoresistant ovarian cancer cell lines. ASCO Meeting Abstracts 2007; 25: 16030.